CervoMed Inc. (NASDAQ:CRVO) on Wednesday shared additional data from its Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies (DLB). The results are based on the final analyses of ...
The average one-year price target for CervoMed (NasdaqCM:CRVO) has been revised to $22.88 / share. This is an increase of 13.77% from the prior estimate of $20.11 dated November 7, 2025. The price ...
Fintel reports that on November 4, 2025, D. Boral Capital maintained coverage of CervoMed (NasdaqCM:CRVO) with a Buy recommendation. As of October 30, 2025, the average one-year price target for ...
An update from CervoMed ( (CRVO)) is now available. CervoMed reported first-quarter 2026 results on May 18, 2026, highlighting continued progress with its lead candidate neflamapimod across multiple ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Urogen Pharma (URGN) and CervoMed (CRVO) with bullish sentiments. According to TipRanks.com, Bancroft is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results